A mouse retinal explant model for use in studying neuroprotection in glaucoma

Ushasree Pattamatta; Zachary McPherson; Andrew White

doi:10.1016/j.exer.2016.07.010

A mouse retinal explant model for use in studying neuroprotection in glaucoma

Exp Eye Res. 2016 Oct:151:38-44. doi: 10.1016/j.exer.2016.07.010. Epub 2016 Jul 21.

Authors

Ushasree Pattamatta¹, Zachary McPherson², Andrew White³

Affiliations

¹ Glaucoma Cell Biology Group, The Westmead Institute for Medical Research, NSW, Australia; Discipline of Ophthalmology, School of Medicine, University of Sydney, NSW, Australia. Electronic address: Ushasree.pattamatta@sydney.edu.au.
² Glaucoma Cell Biology Group, The Westmead Institute for Medical Research, NSW, Australia; School of Medicine and Public Health, University of Newcastle, NSW, Australia.
³ Glaucoma Cell Biology Group, The Westmead Institute for Medical Research, NSW, Australia; Discipline of Ophthalmology, School of Medicine, University of Sydney, NSW, Australia; Save Sight Institute, University of Sydney, NSW, Australia.

PMID: 27450912
DOI: 10.1016/j.exer.2016.07.010

Abstract

The study aims to validate mouse retinal explants for use as an efficient tool to investigate neuroprotective therapies for treatment in diseases such as glaucoma. Eyes from C57BL/6 mice were enucleated immediately post-mortem to make two retinal explants per eye. Explants were cultured at an air/medium interface on membrane inserts for 7 days ex-vivo. Explants were treated either with Z-VAD-FMK (a pan-caspase inhibitor; 100 μM) or vehicle. Retinal Ganglion cell (RGC) density was analysed by βIII tubulin and RNA-binding protein with multiple splicing (RBPMS) immunohistochemistry. Caspase activity was measured using Caspase 3/7 glo assay and western blot. Caspase-3 expression was quantified using RT-PCR and western blotting. Retinal explants treated with Z-VAD-FMK demonstrated a 1.5-fold (p = 0.027) increase in number of surviving RGCs on day 4 compared to the control treatment using βIII tubulin staining. RGC viability was 2-fold (p = 0.002) higher in RGC stained with RBPMS on day 1 compared to control. There was no RBPMS staining of RGCs beyond day 1 in either treatment. The caspase activity was 4.75 and 5.5-fold (p = 0.002 and 0.004 respectively) higher in control as compared to treatment with Z-VAD-FMK on day 1, 2 respectively. Increase in caspase activity in control group was also confirmed by western blot for day 1 protein lysates. Caspase-3 mRNA expression was 4.75-fold higher in Z-VAD-FMK treated explants compared to control on day 1 (p < 0.001). Culture conditions appropriate to retinal explant culture for investigation of RGC apoptosis was identified. Retinal cultures at day 4 were ideal for detecting neuroprotection using βIII tubulin staining. RBPMS acts as a viability marker as well as to define best time point for investigation of apoptosis related signalling pathways which is day 1. These findings suggest that mouse retinal explants are good model for studying ganglion cell specific apoptosis and are applicable to diseases such as glaucoma.

Keywords: Apoptosis; Glaucoma; Neuroprotection; Retinal explant.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Apoptosis
Blotting, Western
Caspases / biosynthesis*
Caspases / genetics
Cell Survival
Disease Models, Animal
Gene Expression Regulation
Glaucoma / pathology
Glaucoma / physiopathology
Glaucoma / therapy*
Immunohistochemistry
Male
Mice
Mice, Inbred C57BL
Neuroprotection / physiology*
Organ Culture Techniques
RNA / genetics
Real-Time Polymerase Chain Reaction
Retinal Ganglion Cells / cytology*
Retinal Ganglion Cells / metabolism
Signal Transduction

Substances

RNA
Caspases